Abstract:Metastatic melanoma patients are commonly treated with targeted (e.g., BRAF/MEK inhibitors) and/or immune checkpoint therapies and treatment efficacy is then assessed with radiological scans. These scans are highly effective for the staging of the disease but in terms of follow-up, there are several limitations including the inability to detect minimal residual disease (MRD). Circulating biomarkers are a viable solution to overcome these limitations, and this study sought to investigate a panel of melanoma-specific microRNA (miRNA) biomarkers in stage IV patients undergoing therapy. This panel had previously been assessed in treatment naïve stage IV patients, with members of the MELmiR-7 panel able to detect an increase in tumor burden in 100% of cases, as well as the ability to define overall survival (OS) superior to serum lactate dehydrogenase (LDH) and S100B levels (delta log-likelihood = 11, p< 0.001). In this multi-center longitudinal study, bloods were drawn from study participants from 2013-2015, with clinical follow-up until October 2018. The expression levels of the MELmiR-7 panel were assessed in serially collected serum (≥3 timepoints; ≥2-month intervals) collected from a total of 23 melanoma patients, treated with BRAF/MEK inhibitors and/or anti-CTLA4 and/or anti-PD-1. The goal was to determine if the panel could predict treatment success/failure, as well as patient OS, if treated with the same therapy. All miRNA panel members were measured using a sensitive real-time PCR assay at each time point, but only miR-4731 gave stable expression over the course of the therapy, with other panel members fluctuating post treatment. The stability of miR-4731 expression over time indicated that this marker was not affected by treatment type, rather changes in its expression were reflective of disease progression/regression (as determined by radiological images), thus making it an ideal biomarker. Importantly, across the cohort of 23 patients, miR-4731 expression had the ability to predict treatment outcome (Complete Response/Stable Disease (n=12) vs Melanoma Death (n=11)) for patients at ≥2 months post therapy vs baseline, with a high degree of precision (Mann Whitney, 2-tailed; p=0.0004). Area under the curve analysis also found miR-4731 expression to be highly sensitive and specific (AUC=0.91; p=0.0009) at predicting overall survival (OS). Furthermore, in Kaplan-Meier survival analysis, participants with high serum expression (≥2 months post therapy vs baseline) of miR-4731, had poor OS (p=0.0045; 14-month median survival) as compared with low serum miRNA expression which was predictive of a positive prognosis. In sum, assessment of this miRNA marker during therapy would permit early on-treatment prediction of patient outcomes, independent of imaging, to either continue to treat with current regimen, or to switch treatment modalities. Citation Format: Teresa Harris, Pauline Zaenker, Ashleigh C. McEvoy, H. Peter Soyer, Muhammad A. Khattak, Melanie Ziman, Michael Millward, Elin S. Gray, Mitchell S. Stark. Assessment of precision melanoma diagnostics: Circulating microrna expression to monitor late-stage treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7626.

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors

Stage-specific prognostic biomarkers in melanoma.

Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy

Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy

Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma

Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study

Metabolic Imaging Biomarkers of Response to Signaling Inhibition Therapy in Melanoma

A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report

Outcomes in patients with BRAFV600–mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis

Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine

Abstract 7626: Assessment of precision melanoma diagnostics: Circulating microrna expression to monitor late-stage treatment

Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients

Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer